莫西沙星与头孢哌酮/舒巴坦治疗老年患者下呼吸道感染的评价

Clinical application value of moxifloxacin and cefoperazone-sulbactam in treatment of elderly patients with lower respiratory tract infections

目的探讨莫西沙星与头孢哌酮/舒巴坦在治疗老年患者中重度下呼吸道感染的临床疗效与安全性。方法选取2011年9月-2013年10月254例中重度下呼吸道感染的老年患者随机分为莫西沙星组(A组)、头孢哌酮/舒巴坦组(B组)和对照组(C组),在常规对症治疗的基础上,A组87例给予莫西沙星治疗,B组82例给予头孢哌酮/舒巴坦治疗,C组85例给予头孢他啶治疗,对比分析3组患者临床疗效与安全性。结果 A组与B组在痊愈率、总有效率、症状改善时间和治疗总时间差异均无统计学意义;A组的痊愈率和总有效率高于C组,A组的症状改善时间和治疗总时间比C组短,差异均有统计学意义(P<0.05);B组的痊愈率和总有效率高于C组,B组的症状改善时间和治疗总时间比C组短,差异均有统计学意义(P<0.05);不良反应发生率A组为4.6%、B组为3.7%、C组为4.7%,3组患者的不良反应发生率差异无统计学意义。结论莫西沙星和头孢哌酮/舒巴坦两个抗菌药物在治疗老年患者下呼吸道感染时临床疗效显著,不良反应发生率均较低、安全性较好。

OBJECTIVE To explore the clinical efficacy and safety of moxifloxacin and cefoperazone-sulbactam in treatment of elderly patients with severe lower respiratory tract infections.METHODS From Sep 2011 to Oct 2013,a total of 254 elderly patients with severe lower respiratory tract infections were randomly divided into the moxifloxacin group（group A）,the cefoperazone-sulbactam group（group B）,and the control group（group C）.On the basis of the conventional symptomatic treatment,the group A with 87 cases was treated with moxifloxacin,the group B with 82 cases was given cefoperazone-sulbactam,and the group C with 85 cases was treated with ceftazidime.The clinical efficacy and safety were observed and compared among the three groups.RESULTS There was no significant difference in the cure rate,total effective rate,time of improvement of symptoms,or total treatment time between the group A and the group B.The cure rate and total effective rate of the group A were higher than those of the group C,the time of improvement of symptoms and total treatment time of the group A were shorter than those of the group C,and the difference was significant（P〈0.05）.The cure rate and total effective rate of the group B were higher than those of the group C,the time of improvement of symptoms and total treatment time of the group B were shorter than those of the group C,and the difference was significant（P〈0.05）.The incidence of adverse reactions was 4.6%in the group A,3.7%in the group B,4.7%in the group C,and there was no significant difference in the incidence of adverse reactions among the three groups.CONCLUSIONS As compared with ceftazidime,moxifloxain and cefoperazone-sulbactam can achieve significant efficacy in treatment of the elderly patients with lower respiratory tract infections,and there is no significant difference between the two groups.The incidence of adverse reactions is low,and the safety is good.